Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.45 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13188961 | 0.81 | NAMPT (0.44) | P2RX3P2RX2 | |
| SCHEMBL15436226 | 0.79 | NAMPT (0.40) | — | |
| SCHEMBL452119 | 0.77 | P2RX3 (0.51) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 | |
| SCHEMBL454836 | 0.74 | KDM4C (0.48) | — | |
| SCHEMBL13092673 | 0.73 | NR1I2 (0.57) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 | |
| SCHEMBL13092853 | 0.73 | NR1I2 (0.67) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 | |
| SCHEMBL451719 | 0.73 | P2RX3 (0.47) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 | |
| SCHEMBL16504248 | 0.71 | NR1I2 (0.54) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 | |
| SCHEMBL453785 | 0.71 | P2RX3 (0.49) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 | |
| SCHEMBL1069831 | 0.70 | NR1I2 (0.70) | P2RX3P2RX2NR1I2CYP2C9UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | P2RX3 1/4885P2RX2 3/4885NR1I2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.